Charlie Sheppard

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.

HatchBox Bioconsulting LLC provides life science advisory services.

Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA.

Brilliant Group, Inc. manufactures fluorescent pigment services. It manufactures daylight fluorescent pigments, colorants, and ink concentrates for the paints, inks, plastics, textiles, stationery, craft, and other markets. The company was founded by Darren Bianchi in 2007 and is headquartered in Richmond, CA.

Radiant Color NV is engaged in the production and marketing of fluorescent pigments. Its products include dispersions, special color concentrates, and effect colorants. The company was founded in 1966 and is headquartered in Houthalen, Belgium.

Nanogap Sub NM Powder SA provides research and development of nanotechnology materials. It serves in the medical, electronic and packaging industries. The firm offers atomic quantum clusters and nanoparticle dispersions in a variety of carrier liquids and solutions. The company was founded by Jose Rivas, Tatiana Lopez del Rio, Vazquez Carlos Vazquez and Arturo Lopez Quintelas in 2006 and is headquartered in Ames, Spain.

BioNeex, Inc. is an American company located in Syracuse, NY, that operates as a drug development platform. It was founded by Smbat Rafayelyan and Tigran Rafayelyan. Smbat Rafayelyan has been the CEO since 2018. The company says this about itself: BioNeex is the first R&D open exchange platform in the biopharma industry, facilitating licensing and co-development partnerships for preclinical and clinical-stage drug candidates between biotech, biopharma companies and research institutions. Data posted on the drug candidate marketplace is listed by biotech, biopharma companies, and research institutions, enabling potential licensing and co-development partners as well as investors to contact them directly with one click.

Vantage Biosciences Ltd. develops drugs for diabetic eye disease. The British company was founded by Andre Badalyan, Katie Sunnucks, Graeme R. Martin, Alek Safarian.

DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom.

Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom.

Scioto Biosciences, Inc. operates as a preclinical stage company. It develops therapies to transform the delivery of microbiome therapeutics. The firm?s platform enhances probiotics that are used for diabetes, neurological disorders, gastrointestinal health and alternatives to in-feed antibiotics. The company was founded by Joseph P. Trebley, Jim Schulz, Goodman Steve, Lauren O. Bakaletz, Michael Bailey and Gail E. Besner in May 2017 and is headquartered in Indianapolis, IN.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

BioMotiv LLC operates as a research institution in the field of therapeutics. It focuses in disease areas and classes of therapeutics such as small molecules, antibodies, proteins, and nucleotides. The company was founded on September 10, 2012 and is headquartered in Cleveland, OH.

ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.